4 results on '"Nappi,O"'
Number of results to display per page
Search Results
2. High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
- Author
-
DAlterio, C., Portella, L., Ottaiano, A., Rizzo, M., Carteni, G., Pignata, S., Facchini, G., Perdona, S., Di Lorenzo, G., Autorino, R., Franco, R., La Mura, A., Nappi, O., Castello, G., and Scala, S.
- Abstract
Background: Almost 30 of the sunitinib-treated patients for metastatic renal carcinoma (mRCC) do not receive a clinical benefit. Convincing evidences demonstrated a cross talk between the VEGF and CXCR4 pathways. It was hypothesized that CXCR4 expression in primary renal cancer could predict sunitinib responsiveness. Patients and Methods: In this exploratory study sixty-two mRCC patients receiving sunitinib as first-line treatment were evaluated for CXCR4 expression through immunohistochemistry (IHC). Correlations between CXCR4 expression, baseline patients and tumour characteristics were studied by contingency tables and the chi-square test. Univariable analysis was performed with the log-rank test, and the Cox model was applied for multivariable analysis. Results: The objective response rate of sunitinib first-line therapy was 35.5 (22/62) with a disease control rate (response and stable disease) of 62.9 (39/62). CXCR4 expression was absent/low in 30 (48.4), moderate in 17 (27.4), and high in 15 (24.2) tumors respectively. Low or absent CXCR4 expression predicted response to sunitinib therapy. Moreover, Fuhrman grading and concomitant, CXCR4 and Fuhrman grading, strongly predicted sunitinib first line therapy responsiveness on progression-free survival and overall survival. Conclusions: High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer
- Published
- 2012
3. High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
- Author
-
Giacomo Cartenì, A. La Mura, S. Perdonà, Luigi Portella, Crescenzo D'Alterio, Sandro Pignata, Gaetano Facchini, Oscar Nappi, G. Di Lorenzo, Stefania Scala, Riccardo Autorino, Renato Franco, Giuseppe Castello, Alessandro Ottaiano, Mino Rizzo, D' Alterio, C, Portella, L, Ottaiano, A, Rizzo, M, Carteni, G, Pignata, S, Facchini, G, Perdona, S, Di Lorenzo, G, Autorino, Riccardo, Franco, Renato, La Mura, A, Nappi, O, Castello, G, and Scala, S.
- Subjects
Male ,Oncology ,Cancer Research ,Pathology ,Indoles ,Time Factors ,Angiogenesis Inhibitors ,Kaplan-Meier Estimate ,urologic and male genital diseases ,CXCR4 ,Risk Factors ,Drug Discovery ,Sunitinib ,Aged, 80 and over ,Middle Aged ,Immunohistochemistry ,Kidney Neoplasms ,Treatment Outcome ,Italy ,Predictive value of tests ,Female ,medicine.drug ,Adult ,Receptors, CXCR4 ,medicine.medical_specialty ,Risk Assessment ,Disease-Free Survival ,Predictive Value of Tests ,Cell Line, Tumor ,Internal medicine ,Biomarkers, Tumor ,medicine ,Carcinoma ,Humans ,Pyrroles ,RNA, Messenger ,Carcinoma, Renal Cell ,Grading (tumors) ,Aged ,Proportional Hazards Models ,Pharmacology ,Chi-Square Distribution ,Proportional hazards model ,business.industry ,medicine.disease ,Concomitant ,Multivariate Analysis ,Neoplasm Grading ,business - Abstract
Background: Almost 30% of the sunitinib-treated patients for metastatic renal carcinoma (mRCC) do not receive a clinical benefit. Convincing evidences demonstrated a cross talk between the VEGF and CXCR4 pathways. It was hypothesized that CXCR4 expression in primary renal cancer could predict sunitinib responsiveness. Patients and Methods: In this exploratory study sixty-two mRCC patients receiving sunitinib as first-line treatment were evaluated for CXCR4 expression through immunohistochemistry (IHC). Correlations between CXCR4 expression, baseline patients and tumour characteristics were studied by contingency tables and the chi-square test. Univariable analysis was performed with the log-rank test, and the Cox model was applied for multivariable analysis. Results: The objective response rate of sunitinib first-line therapy was 35.5% (22/62) with a disease control rate (response and stable disease) of 62.9% (39/62). CXCR4 expression was absent/low in 30 (48.4%), moderate in 17 (27.4%), and high in 15 (24.2%) tumors respectively. Low or absent CXCR4 expression predicted response to sunitinib therapy. Moreover, Fuhrman grading and concomitant, CXCR4 and Fuhrman grading, strongly predicted sunitinib first line therapy responsiveness on progression-free survival and overall survival. Conclusions: High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer
- Published
- 2012
4. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
- Author
-
D' Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, and Scala S
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell secondary, Cell Line, Tumor, Chi-Square Distribution, Disease-Free Survival, Female, Humans, Immunohistochemistry, Italy, Kaplan-Meier Estimate, Kidney Neoplasms genetics, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Predictive Value of Tests, Proportional Hazards Models, RNA, Messenger metabolism, Receptors, CXCR4 genetics, Risk Assessment, Risk Factors, Sunitinib, Time Factors, Treatment Outcome, Angiogenesis Inhibitors therapeutic use, Biomarkers, Tumor metabolism, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell immunology, Indoles therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms immunology, Pyrroles therapeutic use, Receptors, CXCR4 metabolism
- Abstract
Background: Almost 30% of the sunitinib-treated patients for metastatic renal carcinoma (mRCC) do not receive a clinical benefit. Convincing evidences demonstrated a cross talk between the VEGF and CXCR4 pathways. It was hypothesized that CXCR4 expression in primary renal cancer could predict sunitinib responsiveness., Patients and Methods: In this exploratory study sixty-two mRCC patients receiving sunitinib as first-line treatment were evaluated for CXCR4 expression through immunohistochemistry (IHC). Correlations between CXCR4 expression, baseline patients and tumour characteristics were studied by contingency tables and the chi-square test. Univariable analysis was performed with the log-rank test, and the Cox model was applied for multivariable analysis., Results: The objective response rate of sunitinib first-line therapy was 35.5% (22/62) with a disease control rate (response and stable disease) of 62.9% (39/62). CXCR4 expression was absent/low in 30 (48.4%), moderate in 17 (27.4%), and high in 15 (24.2%) tumors respectively. Low or absent CXCR4 expression predicted response to sunitinib therapy. Moreover, Fuhrman grading and concomitant, CXCR4 and Fuhrman grading, strongly predicted sunitinib first line therapy responsiveness on progression-free survival and overall survival., Conclusions: High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.